22 research outputs found
Monthly observed deaths, predicted deaths and predicted baseline (Poisson model), South Africa, 1999–2009.
<p><b>A:</b> Pulmonary tuberculosis deaths in individuals <65 years of age. <b>B:</b> Pulmonary tuberculosis deaths in individuals ≥65 years of age; <b>C</b> Non-tuberculosis respiratory deaths in individuals <65 years of age. <b>D</b> Non-tuberculosis respiratory deaths in individuals ≥65 years of age.</p
Monthly detection rate (i.e., monthly number of positive specimens divided by total specimens) of influenza (all ages) in South Africa, 1999–2009.
<p>Monthly detection rate (i.e., monthly number of positive specimens divided by total specimens) of influenza (all ages) in South Africa, 1999–2009.</p
Number of specimens testing positive for influenza and detection rates by year, Viral Watch, South Africa, 2005–2009.
<p>Number of specimens testing positive for influenza and detection rates by year, Viral Watch, South Africa, 2005–2009.</p
Influenza detections and detection rates for seasonal influenza (N = 2490) and influenza A(H1N1)pdm09 (N = 496) by age group, Viral Watch, South Africa: 2005–2009.
<p>Influenza detections and detection rates for seasonal influenza (N = 2490) and influenza A(H1N1)pdm09 (N = 496) by age group, Viral Watch, South Africa: 2005–2009.</p
Vaccination coverage<sup>*</sup> and vaccine effectiveness by year, Viral Watch, South Africa: 2005–2009.
<p><b>Statistically significant values in bold.</b></p>*<p>The proportion of individuals who received at least one dose of influenza vaccine in the relevant period.</p><p>Age groups: <50 and ≥50 years.</p
Percentage of influenza positives by age group and virus type, Viral Watch, South Africa; 2005–2009.
<p>Percentage of influenza positives by age group and virus type, Viral Watch, South Africa; 2005–2009.</p
Comparison of vaccine composition to circulating viruses, South Africa, 2005–2009.
<p><b>Predominating circulating strains in bold.</b></p><p><b>Predominating B strains indicated.</b></p
Additional file 1: of Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa
Assessing the Impact of Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease Using Polymerase Chain Reaction-Based Surveillance: An Experience from South Africa (Supplementary Material). (DOCX 65 kb
Number of patients testing influenza positive by subtype and influenza detection rate by epidemiologic week and year among patients hospitalized with severe acute respiratory illness at four sentinel surveillance sites, South Africa, 2009–2013.
<p>Number of patients testing influenza positive by subtype and influenza detection rate by epidemiologic week and year among patients hospitalized with severe acute respiratory illness at four sentinel surveillance sites, South Africa, 2009–2013.</p
Number of patients enrolled with SARI and influenza, pneumococcal and respiratory syncytial virus (RSV) detection rates by epidemiologic week and year at four sentinel surveillance sites, South Africa, 2009–2011.
<p>Number of patients enrolled with SARI and influenza, pneumococcal and respiratory syncytial virus (RSV) detection rates by epidemiologic week and year at four sentinel surveillance sites, South Africa, 2009–2011.</p